{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Niziol J"],"funding":["NIH SIG","The National Science Foundation","NCRR NIH HHS","Narodowe Centrum Nauki","the Murdock Charitable Trust Foundation"],"pagination":["5827-5841"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7413895"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["412(23)"],"pubmed_abstract":["Kidney cancer is one of the most frequently diagnosed and the most lethal urinary cancer. Despite all the efforts made, no serum-specific biomarker is currently used in the clinical management of patients with this tumor. In this study, comprehensive high-resolution proton nuclear magnetic resonance spectroscopy (<sup>1</sup>H NMR) and silver-109 nanoparticle-enhanced steel target laser desorption/ionization mass spectrometry (<sup>109</sup>AgNPET LDI MS) approaches were conducted, in conjunction with multivariate data analysis, to discriminate the global serum metabolic profiles of kidney cancer (n = 50) and healthy volunteers (n = 49). Eight potential biomarkers have been identified using <sup>1</sup>H NMR metabolomics and nine mass spectral features which differed significantly (p < 0.0"],"journal":["Analytical and bioanalytical chemistry"],"pubmed_title":["Nuclear magnetic resonance and surface-assisted laser desorption/ionization mass spectrometry-based serum metabolomics of kidney cancer."],"pmcid":["PMC7413895"],"funding_grant_id":["1S10RR13878 and 1S10RR026659","2015066:MNL","2016/23/B/ST4/00062","S10 RR026659","NSF-MRI:DBI-1532078"],"pubmed_authors":["Copie V","Tripet BP","Arendowski A","Niziol J","Ruman T","Ossolinski K"],"additional_accession":[]},"is_claimable":false,"name":"Nuclear magnetic resonance and surface-assisted laser desorption/ionization mass spectrometry-based serum metabolomics of kidney cancer.","description":"Kidney cancer is one of the most frequently diagnosed and the most lethal urinary cancer. Despite all the efforts made, no serum-specific biomarker is currently used in the clinical management of patients with this tumor. In this study, comprehensive high-resolution proton nuclear magnetic resonance spectroscopy (<sup>1</sup>H NMR) and silver-109 nanoparticle-enhanced steel target laser desorption/ionization mass spectrometry (<sup>109</sup>AgNPET LDI MS) approaches were conducted, in conjunction with multivariate data analysis, to discriminate the global serum metabolic profiles of kidney cancer (n = 50) and healthy volunteers (n = 49). Eight potential biomarkers have been identified using <sup>1</sup>H NMR metabolomics and nine mass spectral features which differed significantly (p < 0.0","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 Sep","modification":"2026-06-01T18:16:22.507Z","creation":"2025-02-19T00:59:12.545Z"},"accession":"S-EPMC7413895","cross_references":{"pubmed":["32661677"],"doi":["10.1007/s00216-020-02807-1"]}}